Scholarlink

<p>Benign prostatic hyperplasia (BPH) is the most common urological condition among elderly men. Because of modifiable metabolic risk factors, the prevalence of BPH is rising. This study aimed to investigate the therapeutic potential of ripasudil, a Rho kinase inhibitor, and also its combination with finasteride in attenuating testosterone-induced BPH in male Wistar rats. Rats were given testosterone propionate (3&#xa0;mg/kg/day) for 4&#xa0;weeks to develop BPH and were treated with ripasudil (3&#xa0;mg/kg/day), finasteride (5&#xa0;mg/k/day), or a combination of both concomitant the testosterone injection throughout the course of the study. The results revealed a significant increase in prostate index, a rise in prostate-specific antigen (PSA), and characteristic histopathological changes indicative of BPH post-testosterone administration. Additionally, testosterone induced elevation in inflammatory markers (interleukin-6 (IL-6), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β), and nuclear factor-κB (NF-κB)), oxidative stress (increase in malondialdehyde (MDA) and decrease in glutathione (GSH)), and elevation of Rho kinase1 (ROCK1). However, intervention with ripasudil or its combination with finasteride effectively mitigated these changes possibly via anti-inflammatory, antioxidative, and ROCK inhibition properties. These findings highlight the potential of ripasudil as adjunctive therapies for BPH, offering an approach for targeting inflammation, oxidative stress, and ROCK pathways. Further research is needed to clarify the underlying mechanisms driving these therapeutic effects and validate these findings in clinical settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: targeting inflammation, oxidative stress, and Rho kinase pathways

  • 期刊论文

  • 发表日期：

    2025年4月29日

查看全文
  • Randa Hisham Aljorani,
  • Adeeb Ahmed Al-Zubaidy,
  • Nibrass Taher Abdali

摘要

Benign prostatic hyperplasia (BPH) is the most common urological condition among elderly men. Because of modifiable metabolic risk factors, the prevalence of BPH is rising. This study aimed to investigate the therapeutic potential of ripasudil, a Rho kinase inhibitor, and also its combination with finasteride in attenuating testosterone-induced BPH in male Wistar rats. Rats were given testosterone propionate (3 mg/kg/day) for 4 weeks to develop BPH and were treated with ripasudil (3 mg/kg/day), finasteride (5 mg/k/day), or a combination of both concomitant the testosterone injection throughout the course of the study. The results revealed a significant increase in prostate index, a rise in prostate-specific antigen (PSA), and characteristic histopathological changes indicative of BPH post-testosterone administration. Additionally, testosterone induced elevation in inflammatory markers (interleukin-6 (IL-6), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α), transforming growth factor-beta (TGF-β), and nuclear factor-κB (NF-κB)), oxidative stress (increase in malondialdehyde (MDA) and decrease in glutathione (GSH)), and elevation of Rho kinase1 (ROCK1). However, intervention with ripasudil or its combination with finasteride effectively mitigated these changes possibly via anti-inflammatory, antioxidative, and ROCK inhibition properties. These findings highlight the potential of ripasudil as adjunctive therapies for BPH, offering an approach for targeting inflammation, oxidative stress, and ROCK pathways. Further research is needed to clarify the underlying mechanisms driving these therapeutic effects and validate these findings in clinical settings.